false2023-06-302023Q20001809196--12-31 0001809196 2023-06-30 0001809196 2022-12-31 0001809196 2022-01-01 2022-06-30 0001809196 2023-01-01 2023-06-30 0001809196 2022-04-01 2022-06-30 0001809196 2023-04-01 2023-06-30 0001809196 2022-06-30 0001809196 2021-12-31 0001809196 imtx:BMSCollaborationAgreementMember 2023-04-01 2023-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2023-04-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2023-04-01 2023-06-30 0001809196 country:GB imtx:GSKCollaborationAgreementMember 2023-04-01 2023-06-30 0001809196 imtx:CollaborationAgreementsMember 2023-04-01 2023-06-30 0001809196 imtx:BMSOptInAgreementMember 2023-04-01 2023-06-30 0001809196 imtx:ServiceOptionsMember imtx:KeyManagementPersonnelAndBoardOfDirectorsMember 2023-04-01 2023-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001809196 country:DE imtx:ImmaticsBiotechnologiesGmbhMember 2022-04-01 2022-06-30 0001809196 country:DK imtx:GenmabCollaborationAgreementMember 2022-04-01 2022-06-30 0001809196 country:US imtx:BMSCollaborationAgreementMember 2022-04-01 2022-06-30 0001809196 imtx:GSKCollaborationAgreementMember country:GB 2022-04-01 2022-06-30 0001809196 imtx:CollaborationAgreementsMember 2022-04-01 2022-06-30 0001809196 ifrs-full:OtherReservesMember 2022-01-01 2022-06-30 0001809196 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001809196 ifrs-full:SharePremiumMember 2022-01-01 2022-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001809196 ifrs-full:IssuedCapitalMember 2022-01-01 2022-06-30 0001809196 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-06-30 0001809196 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-01-01 2022-06-30 0001809196 imtx:CurrentlyReportedMember 2022-01-01 2022-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2022-01-01 2022-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2022-01-01 2022-06-30 0001809196 country:GB imtx:GSKCollaborationAgreementMember 2022-01-01 2022-06-30 0001809196 imtx:CollaborationAgreementsMember 2022-01-01 2022-06-30 0001809196 ifrs-full:OtherReservesMember 2023-01-01 2023-06-30 0001809196 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001809196 ifrs-full:SharePremiumMember 2023-01-01 2023-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2023-01-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2023-01-01 2023-06-30 0001809196 imtx:NonInterestBearingLiabilityMember 2023-01-01 2023-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2023-01-01 2023-06-30 0001809196 imtx:MatchingStockOptionsMember 2023-01-01 2023-06-30 0001809196 imtx:ConvertedOptionsMember 2023-01-01 2023-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2023-01-01 2023-06-30 0001809196 imtx:GrantedOnMarchTwoThousandAndTwentyOneMember imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2023-01-01 2023-06-30 0001809196 imtx:GrantedOnSeptemberTwoThousandAndTwentyOneMember imtx:PerformanceBasedOptionsMember 2023-01-01 2023-06-30 0001809196 imtx:GrantedOnJuneTwoThousandAndTwentyMember imtx:ConvertedOptionsMember 2023-01-01 2023-06-30 0001809196 imtx:MatchingStockOptionsMember 2023-01-01 2023-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001809196 ifrs-full:IssuedCapitalMember 2023-01-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember imtx:Ima401Member 2023-01-01 2023-06-30 0001809196 imtx:AtTheMarketAgreementMember imtx:SvbSecuritiesLlcMember 2023-01-01 2023-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2023-01-01 2023-06-30 0001809196 country:US imtx:BMSCollaborationAgreementMember 2023-01-01 2023-06-30 0001809196 imtx:GSKCollaborationAgreementMember country:GB 2023-01-01 2023-06-30 0001809196 imtx:CollaborationAgreementsMember 2023-01-01 2023-06-30 0001809196 imtx:BMSOptInAgreementMember 2023-01-01 2023-06-30 0001809196 imtx:ServiceOptionsMember imtx:KeyManagementPersonnelAndBoardOfDirectorsMember 2023-01-01 2023-06-30 0001809196 ifrs-full:LeaseholdImprovementsMember 2023-01-01 2023-06-30 0001809196 imtx:RentalLandMember 2023-01-01 2023-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2022-12-31 0001809196 imtx:BondsMember ifrs-full:CarryingAmountMember 2022-12-31 0001809196 ifrs-full:AtFairValueMember imtx:BondsMember 2022-12-31 0001809196 ifrs-full:CarryingAmountMember 2022-12-31 0001809196 ifrs-full:AtFairValueMember 2022-12-31 0001809196 imtx:CashAndCashEquivalentsMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2022-12-31 0001809196 imtx:BondsMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2022-12-31 0001809196 ifrs-full:TradeReceivablesMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2022-12-31 0001809196 imtx:OtherCurrentNonCurrentAssetsMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2022-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2022-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:ShorttermDepositsMember 2022-12-31 0001809196 imtx:AccountsPayableMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2022-12-31 0001809196 imtx:OtherCurrentLiabilitiesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2022-12-31 0001809196 imtx:LiabilitiesForWarrantsMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001809196 ifrs-full:LeaseLiabilitiesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2022-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2022-12-31 0001809196 imtx:ReorganizationMember 2022-12-31 0001809196 imtx:CashAndCashEquivalentsMember 2022-12-31 0001809196 imtx:BondsMember 2022-12-31 0001809196 ifrs-full:TradeReceivablesMember 2022-12-31 0001809196 imtx:OtherCurrentNonCurrentAssetsMember 2022-12-31 0001809196 imtx:AccountsPayableMember 2022-12-31 0001809196 imtx:OtherCurrentLiabilitiesMember 2022-12-31 0001809196 imtx:LiabilitiesForWarrantsMember 2022-12-31 0001809196 ifrs-full:LeaseLiabilitiesMember 2022-12-31 0001809196 imtx:ShorttermDepositsMember 2022-12-31 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2023-06-30 0001809196 imtx:CashAndCashEquivalentsMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2023-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:ShorttermDepositsMember 2023-06-30 0001809196 ifrs-full:TradeReceivablesMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2023-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:OtherCurrentNonCurrentAssetsMember 2023-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2023-06-30 0001809196 imtx:AccountsPayableMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-06-30 0001809196 imtx:OtherCurrentLiabilitiesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-06-30 0001809196 imtx:LiabilitiesForWarrantsMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2023-06-30 0001809196 ifrs-full:LeaseLiabilitiesMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2023-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-06-30 0001809196 imtx:ReorganizationMember 2023-06-30 0001809196 imtx:MatchingStockOptionsMember 2023-06-30 0001809196 imtx:ConvertedOptionsMember 2023-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2023-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2023-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheOneMember 2023-06-30 0001809196 imtx:TrancheTwoMember imtx:PerformanceBasedOptionsMember 2023-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheThreeMember 2023-06-30 0001809196 imtx:CashAndCashEquivalentsMember 2023-06-30 0001809196 imtx:ShorttermDepositsMember 2023-06-30 0001809196 ifrs-full:TradeReceivablesMember 2023-06-30 0001809196 imtx:OtherCurrentNonCurrentAssetsMember 2023-06-30 0001809196 imtx:AccountsPayableMember 2023-06-30 0001809196 imtx:OtherCurrentLiabilitiesMember 2023-06-30 0001809196 imtx:LiabilitiesForWarrantsMember 2023-06-30 0001809196 ifrs-full:LeaseLiabilitiesMember 2023-06-30 0001809196 ifrs-full:TopOfRangeMember 2023-06-30 0001809196 imtx:CollaborationAgreementMember 2023-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2022-01-01 2022-12-31 0001809196 imtx:AuthorizationOfFinancialStatementsMember 2023-08-17 2023-08-17 0001809196 imtx:IssueOfSecuritiesMember imtx:SvbSecuritiesLlcMember imtx:AtTheMarketAgreementMember 2023-08-17 2023-08-17 0001809196 ifrs-full:BottomOfRangeMember 2023-03-31 0001809196 ifrs-full:BottomOfRangeMember 2022-03-31 0001809196 ifrs-full:TopOfRangeMember 2022-06-30 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember country:DE 2022-06-30 0001809196 imtx:IssueOfSecuritiesMember 2023-07-19 0001809196 imtx:IssueOfSecuritiesMember 2023-07-19 2023-07-19 0001809196 imtx:IssueOfSecuritiesMember imtx:SvbSecuritiesLlcMember imtx:AtTheMarketAgreementMember 2023-08-17 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2023-04-03 2023-04-03 0001809196 imtx:GrantedInJuneTwoThousandAndTwentyTwoMember imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2023-04-03 2023-04-03 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2023-06-27 2023-06-27 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember imtx:GrantedInJuneTwoThousandAndTwentyTwoMember 2023-06-27 2023-06-27 0001809196 ifrs-full:IssuedCapitalMember 2021-12-31 0001809196 ifrs-full:SharePremiumMember 2021-12-31 0001809196 ifrs-full:RetainedEarningsMember 2021-12-31 0001809196 ifrs-full:OtherReservesMember 2021-12-31 0001809196 ifrs-full:IssuedCapitalMember 2022-06-30 0001809196 ifrs-full:SharePremiumMember 2022-06-30 0001809196 ifrs-full:RetainedEarningsMember 2022-06-30 0001809196 ifrs-full:OtherReservesMember 2022-06-30 0001809196 srt:ScenarioPreviouslyReportedMember 2021-12-31 0001809196 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-12-31 0001809196 imtx:CurrentlyReportedMember 2021-12-31 0001809196 srt:ScenarioPreviouslyReportedMember 2022-06-30 0001809196 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-06-30 0001809196 imtx:CurrentlyReportedMember 2022-06-30 0001809196 ifrs-full:IssuedCapitalMember 2022-12-31 0001809196 ifrs-full:SharePremiumMember 2022-12-31 0001809196 ifrs-full:RetainedEarningsMember 2022-12-31 0001809196 ifrs-full:OtherReservesMember 2022-12-31 0001809196 imtx:MatchingStockOptionsMember 2022-12-31 0001809196 imtx:ConvertedOptionsMember 2022-12-31 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyPlanMember 2022-12-31 0001809196 imtx:PerformanceBasedOptionsMember 2022-12-31 0001809196 ifrs-full:OtherReservesMember 2023-06-30 0001809196 ifrs-full:RetainedEarningsMember 2023-06-30 0001809196 ifrs-full:SharePremiumMember 2023-06-30 0001809196 ifrs-full:IssuedCapitalMember 2023-06-30 iso4217:EUR xbrli:shares xbrli:pure iso4217:USD utr:Year iso4217:EUR xbrli:shares iso4217:USD xbrli:shares imtx:Warrants utr:Y
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule
13a-16
or
15d-16
of the Securities Exchange Act of 1934
August 17, 2023
Commission File Number:
001-39363
 
 
IMMATICS N.V.
 
 
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of Principal Executive Office)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F  ☒                    Form
40-F  ☐
 
 
 
INFORMATION
CONTAINED IN THIS REPORT ON FORM
6-K
On August 17, 2023, Immatics N.V. (the “Company”) issued an interim report for the three and
six-month
periods ended June 30, 2023, which is attached hereto as Exhibit 99.1, and issued a press release announcing the second quarter 2023 financial results for the Company, which is attached hereto as Exhibit 99.2. Additionally, the Company made available an updated investor presentation, which is attached hereto as Exhibit 99.3. The fact that the presentation is being made available and furnished herewith is not an admission as to the materiality of any information contained in the presentation. The information contained in the presentation is being provided as of November 17, 2022 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.
INCORPORATION BY REFERENCE
This
Report
on Form
6-K
(other than Exhibit 99.2 and Exhibit 99.3 hereto) including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form
S-8
(333-249408
and
333-265820)
and the registration statements on Form
F-3
(Registration Nos.
333-258351
and
333-240260)
of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBITS
 
Exhibit Number
  
Description
99.1    Immatics N.V. interim report for the three and six-month periods ended June 30, 2023.
99.2    Press release dated August 17, 2023.
99.3    Corporate presentation dated August 17, 2023
101.INS    Inline XBRL Taxonomy Extension Instance Document
101.SCH    Inline XBRL Taxonomy Extension Schema Document
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document
104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
 
1

Table of Contents
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
       
IMMATICS N.V.
       
Date: August 17, 2023       by:  
/s/ Harpreet Singh
            Harpreet Singh
            Chief Executive Officer
 
 
2